Flash-Player installieren
ScheBo-MediaBox



» Flash-Player installieren
» Watch video in bigger size

ScheBo® · Biotech AG
Netanyastrasse 3
35394 Giessen
Germany

Phone +49 (0)641 / 4996-0
Fax +49 (0)641 / 4996-77
Email-contact

ScheBo® Elastase 1 - Canine

Non-radioactive pancreatic function test for dogs


Weight Loss - Maldigestion in dogs !

Is the pancreas involved?

Weight loss and maldigestion (usually presenting as steatorrhoea) are two of the main clinical symptoms suggestive of pancreatic exocrine insufficiency in dogs. A diagnosis or exclusion of this condition is then required.

Exocrine pancreatic insufficiency is very often only diagnosed as a reason for weight loss, maldigestion and /or steatorrhoea at an advanced stage of disease. However, an early diagnosis of exocrine pancreatic insufficiency allows early initiation of successful treatment with pancreatic enzymes substitution therapy.

ScheBo® Elastase 1- Canine is a non-radioactive and highly sensitive and specific assay for the determination of canine pancreatic elastase 1 (E1) in faeces, which reflects the exocrine capacity of the pancreas.

ScheBo® Elastase 1- Canine is an ELISA test based on monoclonal antibodies and guarantees a reliable diagnosis of exocrine pancreatic insufficiency even under pancreatic enzyme substitution therapy. Using this test exocrine pancreatic insufficiency can be distinguished from intestinal diseases and hepatobiliary disorders affecting the small intestine.


Indications and main advantages

  • Diagnosis or exclusion of exocrine pancreatic insufficiency caused by, for example, pancreatic acinar atrophy, pancreatic cancer, chronic pancreatitis, parasites or stones.
  • E1 is absolutely pancreas-specific.
  • The test is non-radioactive. An isotopic laboratory is not required.
  • A single pea-sized stool sample is sufficient.
  • High stability of pancreatic elastase 1 allows time for convenient mailing.
  • No need to interrupt substitution therapy.
  • There is no need for a 12-hour starvation period, in contrast to the necessary preparation before the cTLI test.




AEO-Certificate
The Main Customs Office of Giessen, Germany issued an AEO-F Certificate (Authorized Economic Operator – Customs Simplifications plus Security and Safety) to ScheBo Biotech AG on September 30, 2011.
read...
Lecture DDW 2011: New molecular markers: M2-PK
Lecture of Prof. Dr. Sybille Mazurek on WEO/OMED Colorectal Cancer Screening Committee Meeting DDW 2011.
read...
Biomarker ′M2-PK′ Identified as Key Enzyme in Cancer Diagnosis and Therapy
Ground Breaking Findings on Understanding Cancer Published in ′Science′
read...
Video: Focus 2010 lecture on M2-PK
The high sensitivity (c.80%) and high specificity (>90%) of the M2-PK stool test for colorectal cancer screening and detection, plus benefits for patients, laboratories and doctors, was presented at Focus 2010
read...
Tumour M2-PK as a stool marker for colorectal cancer
Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients.
read...
Coeliac disease and pancreatic exocrine insufficiency
The data have shown that pancreatic insufficiency, demonstrated by low faecal pancreatic elastase-1 levels, is common in adult coeliac disease patients.
read...
ISO-Certificate
Our ISO-Cerficate as pdf-download.
read...